Hormonal
Engaging in resistance physical activity at least once a week is inversely associated with the prevalence of nonalcoholic fatty liver disease (NAFLD), independent of BMI, nutritional intake, and insulin resistance markers.
To reduce your risk of fatty liver disease, incorporate resistance training into your routine at least once a week. You do not need to lose weight on the scale for this to help; the act of resistance training itself appears to protect the liver, likely by improving how your body handles fat and insulin. While aerobic exercise is good, resistance training showed a stronger independent link to lower liver fat in this study.
Adjusting for sex, engaging in any kind of sports (odds ratio [OR] 0.66, 95% confidence interval [CI] 0.44-0.96 per 1 standard deviation increment in PA score) and resistance exercise (OR 0.61, 95% CI 0.38-0.85) were inversely associated with NAFLD. These associations remained unchanged after adjusting for homeostasis model assessment, most nutritional factors, adiponectin, and resistin. Only the association with resistance PA remained significant with further adjustment for body mass index (OR 0.61, 95% CI 0.44-0.85).
Why this rating
Cross-sectional observational study; cannot establish causality, but adjusts for significant confounders like nutrition and BMI.
Source
Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study
Shira Zelber‐Sagi et al. · Hepatology · 2008
DOI 10.1002/hep.22525
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →